<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article292</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/POINT" style="display:block; margin-bottom:10px;">POINT Original</a></li>
<h2><strong>POINT</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA". The New England Journal of Medicine. Published May 16, 2018.<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does the combination of clopidogrel and aspirin improve outcomes compared to aspirin alone in patients with minor ischemic stroke or high-risk TIA?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with minor ischemic stroke or high-risk TIA, the combination of clopidogrel and aspirin reduced the risk of major ischemic events but increased the risk of major hemorrhage at 90 days compared with aspirin alone.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/><br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, double-blind, parallel-group, randomized, placebo-controlled trial<br/>
- N=4,881 patients<br/>
- Clopidogrel + aspirin vs. aspirin alone<br/>
- Enrolment: May 28, 2010, to December 19, 2017<br/>
- Follow-up: 90 days<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- At least 18 years of age<br/>
- Had a minor ischemic stroke (NIHSS score ≤3) or high-risk TIA (ABCD2 score ≥4) within 12 hours prior<br/>
- Underwent imaging to rule out intracranial hemorrhage or other mimics<br/>
- Major exclusions: Candidates for thrombolysis/thrombectomy, contraindication to aspirin or clopidogrel, anticipated need for NSAID use beyond 7 days<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Clopidogrel (600 mg on day 1, followed by 75 mg per day) + aspirin (50 to 325 mg per day) vs. aspirin alone (same dose range)<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Primary efficacy outcome: Composite of ischemic stroke, myocardial infarction, or death from ischemic vascular causes at 90 days<br/>
- Major hemorrhage was the primary safety outcome<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Lower-than-expected overall event rates, particularly in TIA patients with low ABCD2 scores<br/>
- The study population did not represent moderate-to-severe stroke, cardioembolic stroke, or candidates for thrombolysis/thrombectomy<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
- National Institute of Neurological Disorders and Stroke<br/>
- Sanofi provided clopidogrel and placebo for 75% of patients<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/><p></p>
</div>
</div>
</div>
</div>
</body>
</html>
